产品
编 号：F762673
分子式：C48H67N3O6
分子量：782.06
分子式：C48H67N3O6
分子量：782.06
产品类型
规格
价格
是否有货
结构图
CAS No: 2766451-11-8
产品详情
生物活性：
P-gp inhibitor 3 is an effective P-glycoprotein (P-gp) inhibitor. P-gp inhibitor 3 inhibits the efflux function of P-gp by activating P-gp ATPase. P-gp inhibitor 3 has relatively stronger multidrug resistance (MDR) reversal ability and enhances the anti-tumor activity of Paclitaxel.
体内研究：
P-gp inhibitor 3 (10 mg/kg; i.p., once a day, for 1 to 18 days) significantly enhances the anti-tumor activity of paclitaxel and the tumor suppression rate is 56.24%.Animal Model:Nude mice xenograft tumor model (6-8 weeks old, BALB/c, male)
Dosage:10 mg/kg for P-gp inhibitor 3; 30 mg/kg for paclitaxel
Administration:i.p.; once a day (P-gp inhibitor 3), once every three days (paclitaxel); for 1 to 18 days
Result:Significantly enhanced the anti-tumor activity of paclitaxel and the tumor suppression rate was 56.24%.
体外研究：
P-gp inhibitor 3 (compound 16) (10 μM; 72 hours) has appreciable cytotoxicity in KBV cancer cells, with relatively stronger MDR reversal ability.P-gp inhibitor 3 (2.5, 5, 10 μM ; 3 hours) reverses tumor MDR by inhibiting the efflux function of P-gp.P-gp inhibitor 3 (0.25, 0.5, 1 mM; 5 minutes) can significantly increase ATP consumption in a concentration-dependent manner (pP-gp inhibitor 3 相关抗体:Cell Cytotoxicity AssayCell Line:KBV cells
Concentration:10 μM
Incubation Time:72 hours
Result:Showed appreciable cytotoxicity in KBV cancer cells, and exhibited relatively stronger MDR reversal ability.
Cell Cycle AnalysisCell Line:KBV cells
Concentration:10 μM
Incubation Time:24 hours
Result:Induced apoptosis in KBV cells in the G2/M phase.
P-gp inhibitor 3 is an effective P-glycoprotein (P-gp) inhibitor. P-gp inhibitor 3 inhibits the efflux function of P-gp by activating P-gp ATPase. P-gp inhibitor 3 has relatively stronger multidrug resistance (MDR) reversal ability and enhances the anti-tumor activity of Paclitaxel.
体内研究：
P-gp inhibitor 3 (10 mg/kg; i.p., once a day, for 1 to 18 days) significantly enhances the anti-tumor activity of paclitaxel and the tumor suppression rate is 56.24%.Animal Model:Nude mice xenograft tumor model (6-8 weeks old, BALB/c, male)
Dosage:10 mg/kg for P-gp inhibitor 3; 30 mg/kg for paclitaxel
Administration:i.p.; once a day (P-gp inhibitor 3), once every three days (paclitaxel); for 1 to 18 days
Result:Significantly enhanced the anti-tumor activity of paclitaxel and the tumor suppression rate was 56.24%.
体外研究：
P-gp inhibitor 3 (compound 16) (10 μM; 72 hours) has appreciable cytotoxicity in KBV cancer cells, with relatively stronger MDR reversal ability.P-gp inhibitor 3 (2.5, 5, 10 μM ; 3 hours) reverses tumor MDR by inhibiting the efflux function of P-gp.P-gp inhibitor 3 (0.25, 0.5, 1 mM; 5 minutes) can significantly increase ATP consumption in a concentration-dependent manner (pP-gp inhibitor 3 相关抗体:Cell Cytotoxicity AssayCell Line:KBV cells
Concentration:10 μM
Incubation Time:72 hours
Result:Showed appreciable cytotoxicity in KBV cancer cells, and exhibited relatively stronger MDR reversal ability.
Cell Cycle AnalysisCell Line:KBV cells
Concentration:10 μM
Incubation Time:24 hours
Result:Induced apoptosis in KBV cells in the G2/M phase.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备